NovoCure
NVCR
240 hedge funds and large institutions have $4.99B invested in NovoCure in 2019 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 74 increasing their positions, 83 reducing their positions, and 20 closing their positions.
225% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 20
107% more call options, than puts
Call options by funds: $93M | Put options by funds: $45M
22% more funds holding
Funds holding: 197 → 240 (+43)
20% more capital invested
Capital invested by funds: $4.17B → $4.99B (+$820M)
0.93% less ownership
Funds ownership: 68.93% → 68% (-0.93%)
11% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 83
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$128M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.3M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$53.2M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$45.8M |
| 5 |
BlackRock
New York
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$75.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$61.5M |
| 3 |
DCP
Darsana Capital Partners
New York
|
-$40M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$32.2M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$28.5M |
NVCR Hedge Fund Activity: Q3 2019 in Review
240 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2019, worth a combined $4.99B — up 20% from $4.17B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new NVCR positions and 20 closed out — a net gain of 45 holders — while 74 added to existing stakes and 83 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $128M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $75.9M sold.
- 240 institutional investors held NovoCure (NVCR) as of Q3 2019, up from 197 in Q2 2019.
- Funds reported $4.99B of NovoCure stock for Q3 2019, up 20% quarter-over-quarter.
- 65 funds opened new NovoCure positions in Q3 2019 and 20 closed out, a net change of +45 holders.
- The largest NovoCure buyer in Q3 2019 was Fidelity Investments, an estimated $128M added.
- The largest NovoCure seller in Q3 2019 was Farallon Capital Management, an estimated $75.9M sold.
Based on aggregated 13F filings for Q3 2019.